Monitor for any ATM takedown announcements in the coming days, especially ahead of the June 29 PDUFA date. The shelf effectiveness increases near-term dilution risk, but the binary OLC catalyst could overshadow this. Traders should watch for volume spikes or accelerated sales that signal management is tapping the facility.
Price Chart
Executive Summary
Unicycive Therapeutics' universal shelf registration (S-3) was declared effective by the SEC on June 15, 2026, enabling the company to sell up to $150 million in securities, including a $50 million ATM facility. This immediately increases the risk of dilution for existing shareholders, particularly as the company has been aggressively raising capital and reports a net loss of $12.8 million in Q1 2026. The effectiveness comes just 13 days before the PDUFA date for its lead candidate OLC, creating a high-stakes period where the company could tap the ATM ahead of a binary catalyst.
Key Facts
- Shelf registration (File No. 333-296545) declared effective on June 15, 2026.
- Up to $150 million in securities registered, including a $50 million ATM facility with Guggenheim Securities.
- Company reported a net loss of $12.8 million in Q1 2026 and has already sold $19.6 million via its prior ATM in Q1 2026, plus $11.2 million post-quarter.
- PDUFA date for lead candidate OLC is June 29, 2026 — 13 days after effectiveness.
- Market cap is approximately $195 million, meaning the shelf represents up to ~77% dilution if fully utilized.
Financial Impact
Potential dilution of up to ~77% of current market cap ($150M shelf vs $195M market cap), though actual takedown may be partial.
Risk Factors
- Immediate dilution from ATM sales, potentially ahead of the PDUFA catalyst.
- Failure of OLC at PDUFA could trigger a sharp sell-off, compounded by the overhang of available shares.
- Continued cash burn without a clear path to profitability if OLC is not approved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001996 |
| Document: 9999999995-26-001996-index.html | 9999999995-26-001996 |
| Document: 9999999995-26-001996.txt | 9999999995-26-001996 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | 3 | $4.22 | awaiting T+60 | — | $3.89 (−7.82%) |
Sep 29, 2026 27d ago | 8-K | $4.55 | awaiting T+60 | — | $3.89 (−14.51%) |
Aug 12, 2026 10w ago | 8-K | $5.39 | awaiting T+60 | — | $3.89 (−27.83%) |
Jul 2, 2026 16w ago | 8-K | $5.73 $4.81 | ▼ −16.06% | ▼ −19.06% | $3.89 (−32.11%) |
Jun 22, 2026 18w ago | DEFA14A | $7.87 $4.71 | ▼ −40.15% | ▼ −41.90% | $3.89 (−50.57%) |
Jun 16, 2026 18w ago | EFFECT | $7.17 $5.31 | ▲ +25.94% | ▲ +26.94% | $3.89 (+45.75%) |
Jun 5, 2026 20w ago | S-3 | $6.66 $5.05 | ▲ +24.17% | ▲ +27.23% | $3.89 (+41.59%) |
May 12, 2026 23w ago | 8-K | $8.17 $5.05 | ▼ −38.19% | ▼ −42.57% | $3.89 (−52.39%) |
May 12, 2026 23w ago | Press Release | $8.17 $5.05 | ▲ +38.19% | ▲ +42.57% | $3.89 (+52.39%) |
Apr 6, 2026 29w ago | 8-K | $6.62 $5.28 | ▼ −20.24% | ▼ −33.71% | $3.89 (−41.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers